<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868150</url>
  </required_header>
  <id_info>
    <org_study_id>38527</org_study_id>
    <nct_id>NCT03868150</nct_id>
  </id_info>
  <brief_title>Prevention of Postop Atrial Fibrillation Through Intraoperative Inducibility of Atrial Fibrillation and Amiodarone Treatment</brief_title>
  <official_title>Assessment of Intra-Operative Atrial Fibrillation Inducibility As a Screening Tool to Prevent Post-Operative Atrial Fibrillation With Prophylaxis Amiodarone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing first time cardiac surgery will undergo rapid atrial pacing prior to
      initiation of cardiopulmonary bypass to screen for AF inducibility. Patients with inducible
      AF will be randomized to prophylactic amiodarone treatment versus no treatment. Patients who
      are not inducible to AF will be treated with standard post-operative care. Patients will be
      monitored post-operatively to explore the value of intraoperative inducibility of AF to
      predict POAF and to evaluate whether the combination of intraoperative inducibility and
      precision amiodarone therapy is effective at reducing the incidence of POAF
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the operating room, as part of the open heart surgery, the surgeon will stimulate the
      superior right atrium section of the heart with a pacemaker for 30 seconds just prior to
      starting the heart and lung bypass machine. The stimulation is done to see how sensitive the
      heart is to developing atrial fibrillation. This test result will be documented. The
      procedure will only take 60 seconds out of the entire operation. It does not involve taking
      any samples of tissue or blood. Following this step, if the heart demonstrates atrial
      fibrillation for at least 30 seconds then the participant will then be randomized to either
      receive the prophylactic drug treatment using Amiodarone or to no prophylactic drug
      administration. The participant has a 50% chance of receiving the FDA approved study drug
      Amiodarone. The study arms consist of prophylactic drug administration with Amiodarone, No
      prophylactic drug administration, or no atrial fibrillation reaction after stimulation with
      the pacemaker. The remainder of the surgical procedure will not be affected, and will follow
      routine surgical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized control trial of Amiodarone versus standard of care in patients with intraoperative inducible atrial fibrillation undergoing non emergent first-time cardiac surgery.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decreasing the incidence of Post-Operative Atrial Fibrillation for Cardiac Surgery Patients</measure>
    <time_frame>30 days</time_frame>
    <description>Identify predictors of developing atrial fibrillation in the hope of decreasing post-operative length of stay, the need for anticoagulation, decrease risk of stroke, DVT, and bleeding</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Postoperative Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Inducible Atrial Fibrillation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Amiodarone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inducible Atrial Fibrillation - Standard Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No initial Amiodarone Treatment unless POAF seen on post operative care unit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Inducible Atrial Fibrillation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Amiodarone treatment if POAF seen on post-operative care unit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone Injection</intervention_name>
    <description>Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.</description>
    <arm_group_label>Inducible Atrial Fibrillation</arm_group_label>
    <arm_group_label>Inducible Atrial Fibrillation - Standard Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intraoperative Rapid Atrial Pacing</intervention_name>
    <description>Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.</description>
    <arm_group_label>Inducible Atrial Fibrillation</arm_group_label>
    <arm_group_label>Inducible Atrial Fibrillation - Standard Care</arm_group_label>
    <arm_group_label>Non-Inducible Atrial Fibrillation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for first-time non-emergent open-heart surgery for coronary artery
             bypass graft (CABG) revascularization, valvular repair or replacement, combined CABG
             with valve repair or replacement, or valve sparing aortic root repair

          -  Normal sinus rhythm

          -  No documented history of atrial fibrillation

        Exclusion Criteria:

          -  Prior surgical procedures involving heart surgery and cardiopulmonary bypass

          -  Any prior documented history of atrial fibrillation, atrial flutter or atrial
             tachycardia lasting longer than 30 seconds

          -  Prior history of Amiodarone treatment for the management of supraventricular
             tachy-arrhythmias

          -  Patients requiring surgical treatment of atrial arrhythmias such as pulmonary vein
             isolation or Maze procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anson Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anson Lee, MD</last_name>
    <phone>650-724-7500</phone>
    <email>ansonlee@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anson Lee, MD</last_name>
      <phone>650-724-7500</phone>
    </contact>
    <investigator>
      <last_name>John Niesen, RN, MSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Terrence Pong, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Cyr, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joy Aparicio, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cody Carlton, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Anson M. Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

